Compare NSA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSA | VERA |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | 1458 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | N/A | 2021 |
| Metric | NSA | VERA |
|---|---|---|
| Price | $43.40 | $35.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $34.38 | ★ $81.30 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.39 | $472.48 |
| P/E Ratio | $56.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.43 | $19.07 |
| 52 Week High | $46.47 | $56.05 |
| Indicator | NSA | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 37.42 |
| Support Level | $41.07 | $32.48 |
| Resistance Level | $43.89 | $42.05 |
| Average True Range (ATR) | 1.02 | 2.36 |
| MACD | -0.24 | -0.89 |
| Stochastic Oscillator | 11.73 | 5.86 |
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, RightSpace, Northwest and Move It brands.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.